Testing Rademikibart for asthma or COPD flare-ups
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests an investigational drug called Rademikibart for people having a severe asthma or COPD flare-up that needs emergency care and steroids. The study aims to see if the drug can help control the flare-up faster and reduce the need for more treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a doctor's diagnosis of asthma or COPD and are currently having a flare-up that needs urgent care.
- You are receiving steroids (like prednisone) for this flare-up.
- During this flare-up, your blood test shows a certain type of white blood cell (eosinophil count) at 300 or higher.
- You weigh at least 40 kg (88 lbs) if you have asthma, or 45 kg (99 lbs) if you have COPD, and your BMI is 45 or less.
- You have had at least one flare-up in the past that needed steroid treatment.
- You are not pregnant or breastfeeding, and you do not have certain other health conditions like unstable heart disease or a recent cancer.
- You have not received certain other experimental or immune-modulating drugs recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, depemokimab, given as an injection to help reduce flare-ups (exacerbations) in adults with moderate to severe COPD who have a certain type of inflammation. The goal is to see if it can keep you healthier for longer with fewer serious breathing attacks.
This trial tests an injection called RC1416 for people with moderate-to-severe COPD who still have flare-ups despite using triple inhaler therapy. It may help reduce those flare-ups and improve breathing.
This study tests a new medicine, felcorekibart, to see if it can reduce COPD flare-ups better than a placebo after 52 weeks. It's designed for people with high eosinophils, a type of white blood cell linked to inflammation.
This study tests a new way to improve care for adults with asthma who have had a recent severe attack. It aims to see if better management can prevent future flare-ups.
This trial tests a new medicine called lunsekimig for people with COPD that still causes flare-ups despite standard treatment. It focuses on people with higher blood eosinophils (a type of white blood cell). If you smoke or used to smoke and have had at least 2 moderate or 1 severe flare-up in the past year, this study may be an option.
This study tests a new injected medicine (RC1416) for people with moderate-to-severe asthma that is not well controlled with daily inhalers. It may help reduce asthma attacks and improve breathing.
Hear when a new Asthma Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.